Paclitaxel, Albumin-Bound — CPB 0834 | AETNA Coverage Update

Aetna modified CPB 0834 covering albumin-bound paclitaxel (Abraxane), effective September 26, 2025. Here's what billing teams need to know.

Aetna, a CVS Health company, updated its Abraxane coverage policy under CPB 0834 to expand the list of medically necessary indications for J9264 (injection, paclitaxel protein-bound particles, 1 mg). The revision adds or clarifies coverage for 14 oncology indications — from bladder cancer to vaginal cancer — and tightens the language around continuation of therapy. If your practice bills CPT 96413 through 96417 or J9264 for any taxane-based regimen, this update changes what you need on file to support medical necessity and avoid a claim denial.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	Paclitaxel, Albumin-Bound — CPB 0834
Policy Code	CPB 0834
Change Type	Modified
Effective Date	September 26, 2025
Impact Level	High
Specialties Affected	Medical oncology, hematology/oncology, infusion centers, hospital outpatient
Key Action	Audit active Abraxane prior auth files against the updated 14-indication list and verify ICD-10 codes map to covered indications before billing J9264

---

Aetna Albumin-Bound Paclitaxel Coverage Criteria and Medical Necessity Requirements 2025

The core question in CPB 0834 Aetna billing is whether the patient's diagnosis maps to one of 14 approved indications. Aetna's Abraxane coverage policy is explicit: everything outside those 14 indications is experimental, investigational, or unproven. That's a hard stop, not a gray area.

Aetna defines medical necessity for albumin-bound paclitaxel (Abraxane or its generic equivalents) when billing J9264 across these specific settings. The policy covers both brand-name Abraxane and generic albumin-bound paclitaxel — so the medical necessity bar is the same regardless of which you're administering.

For breast cancer, coverage applies in three situations: recurrent or metastatic disease, following no response to preoperative systemic therapy, or when the patient has a hypersensitivity reaction or contraindication to standard premedications for paclitaxel (J9267) or docetaxel (J9171, J9172). That hypersensitivity substitution language also appears for NSCLC and ovarian cancer. Document those reactions specifically — your authorization file needs that clinical rationale clearly on file.

Biliary tract cancers require combination use with gemcitabine (J9201, J9184, or J9196). The same gemcitabine combination requirement applies to pancreatic adenocarcinoma and ampullary adenocarcinoma. For cutaneous melanoma, Aetna allows single-agent or combination with carboplatin (J9045). For uveal melanoma, only single-agent therapy is covered for metastatic or unresectable disease.

The continuation of therapy standard is straightforward: Aetna considers continued treatment medically necessary as long as there is no evidence of unacceptable toxicity or disease progression. That language should be reflected in your supporting documentation at every reauthorization cycle. Missing or vague documentation of response is one of the fastest paths to a claim denial on continuation requests.

This coverage policy applies to commercial medical plans only. For Medicare patients, Aetna directs you to Medicare Part B criteria separately — CPB 0834 does not govern those claims.

Note on prior authorization: CPB 0834 governs medical necessity criteria for albumin-bound paclitaxel. Prior authorization requirements vary by plan and are not explicitly defined within CPB 0834 itself. Verify authorization requirements for each patient's specific plan through Aetna's authorization portal before submitting claims.

---

Aetna Albumin-Bound Paclitaxel Exclusions and Non-Covered Indications

Aetna's position here is clean and unambiguous. Any indication not listed in the 14 approved categories is considered experimental, investigational, or unproven. Full stop.

That matters practically because Abraxane has been studied in a wide range of tumor types, and oncologists sometimes request it off-label based on emerging trial data. Aetna's billing guidelines do not accommodate that. If the diagnosis code on the claim maps to a tumor type outside the covered list, expect a denial.

Common off-label uses that fall outside CPB 0834's covered list include head and neck cancers and gastric/esophageal tumors. The ICD-10 code set in this policy includes codes for those diagnoses (C07, C11.x, C15.x, C16.x) — but their presence in the broader code table does not mean coverage. Those codes appear in the policy's reference set, not in the approved indication list. Don't let a code appearing in the ICD-10 table create false confidence that Aetna will pay.

---

Coverage Indications at a Glance

---

Aetna Abraxane Billing Guidelines and Action Items 2025

The effective date is September 26, 2025. If you have active authorizations for J9264 that were approved before that date, review them against the updated criteria now.

Prior authorization note: CPB 0834 defines medical necessity criteria — not prior authorization requirements. PA requirements vary by plan. Verify authorization requirements for each patient's specific Aetna plan before submitting, and do not assume that meeting medical necessity criteria under CPB 0834 satisfies any applicable PA requirement.

Copy Action Items

If your oncology mix includes rare tumor types like uveal melanoma or vaginal cancer, talk to your compliance officer before September 26, 2025. The specific line requirements — subsequent treatment, single-agent only — are easy to miss in documentation review, and the reimbursement exposure on denied Abraxane claims is significant.

---

CPT, HCPCS, and ICD-10 Codes for Albumin-Bound Paclitaxel Under CPB 0834

HCPCS Code Covered When Selection Criteria Are Met

Code	Type	Description Copy
J9264	HCPCS	Injection, paclitaxel protein-bound particles, 1 mg

CPT Codes for Administration

CPT code descriptions are proprietary to the AMA and are not reproduced in full here. The source data for CPB 0834 lists the following CPT codes as related to this policy. Verify current descriptions against the AMA CPT codebook before use.

Key ICD-10-CM Diagnosis Codes

Note: The full ICD-10 code set for CPB 0834 includes 411 codes spanning multiple tumor types. The codes above represent the primary diagnosis categories tied to covered indications. Review the full code list at app.payerpolicy.org/p/aetna/0834 before finalizing your charge capture.

---